KRAS and non-small cell lung carcinoma: However, in two phase II studies of selumetinib plus docetaxel without ppG-CSF for patients with treatment-naïve advanced melanoma and pretreated KRAS-mutant advanced NSCLC, increased incidences of grade ≥3 febrile neutropenia were reported compared with placebo (21% vs. 12% and 18% vs. 0%, respectively) [12, 20].